SI3033102T2 - Peptid konjugirani delci - Google Patents

Peptid konjugirani delci

Info

Publication number
SI3033102T2
SI3033102T2 SI201431436T SI201431436T SI3033102T2 SI 3033102 T2 SI3033102 T2 SI 3033102T2 SI 201431436 T SI201431436 T SI 201431436T SI 201431436 T SI201431436 T SI 201431436T SI 3033102 T2 SI3033102 T2 SI 3033102T2
Authority
SI
Slovenia
Prior art keywords
peptide conjugated
conjugated particles
particles
peptide
conjugated
Prior art date
Application number
SI201431436T
Other languages
English (en)
Other versions
SI3033102T1 (sl
Inventor
Lonnie D Shea
Stephen D. Miller
Jonathan Woon Teck Yap
Daniel R. Getts
Derrick Mccarthy
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52468804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3033102(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Northwestern University filed Critical Northwestern University
Publication of SI3033102T1 publication Critical patent/SI3033102T1/sl
Publication of SI3033102T2 publication Critical patent/SI3033102T2/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201431436T 2013-08-13 2014-08-13 Peptid konjugirani delci SI3033102T2 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361865389P 2013-08-13 2013-08-13
US201361869279P 2013-08-23 2013-08-23
US201361887112P 2013-10-04 2013-10-04
EP14836306.2A EP3033102B2 (en) 2013-08-13 2014-08-13 Peptide conjugated particles
PCT/US2014/050962 WO2015023796A2 (en) 2013-08-13 2014-08-13 Peptide conjugated particles

Publications (2)

Publication Number Publication Date
SI3033102T1 SI3033102T1 (sl) 2020-03-31
SI3033102T2 true SI3033102T2 (sl) 2024-03-29

Family

ID=52468804

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431436T SI3033102T2 (sl) 2013-08-13 2014-08-13 Peptid konjugirani delci

Country Status (24)

Country Link
US (9) US9616113B2 (sl)
EP (2) EP3033102B2 (sl)
JP (4) JP6553033B2 (sl)
KR (5) KR20160042079A (sl)
CN (2) CN105555301B (sl)
AU (4) AU2014306603B2 (sl)
BR (1) BR112016003084A2 (sl)
CA (1) CA2918823A1 (sl)
CY (1) CY1122558T1 (sl)
DK (1) DK3033102T4 (sl)
ES (1) ES2762187T5 (sl)
FI (1) FI3033102T4 (sl)
HR (1) HRP20192270T4 (sl)
HU (1) HUE047329T2 (sl)
IL (3) IL292567A (sl)
LT (1) LT3033102T (sl)
ME (1) ME03590B (sl)
MX (5) MX2016001931A (sl)
PL (1) PL3033102T5 (sl)
PT (1) PT3033102T (sl)
RS (1) RS59801B2 (sl)
RU (1) RU2685186C2 (sl)
SI (1) SI3033102T2 (sl)
WO (1) WO2015023796A2 (sl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817755C (en) 2010-11-12 2021-07-06 Rachael Terry Modified immune-modulating particles
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
EP3607973A1 (en) 2012-06-21 2020-02-12 Northwestern University Peptide conjugated particles
IL303425A (en) 2013-03-13 2023-08-01 Cour Pharmaceuticals Dev Company Secondary vaccine particles for the treatment of inflammation
MX2015013894A (es) 2013-04-03 2015-12-11 Allertein Therapeutics Llc Composiciones de nanoparticulas novedosas.
EP3033102B2 (en) 2013-08-13 2023-12-20 Northwestern University Peptide conjugated particles
WO2015200054A2 (en) 2014-06-24 2015-12-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3095440B1 (en) * 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
KR20180059922A (ko) * 2015-10-02 2018-06-05 유니버시티 오브 코펜하겐 히스톤 리더 도메인을 차단하는 소분자
WO2017112828A1 (en) * 2015-12-22 2017-06-29 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US11510996B2 (en) 2015-12-23 2022-11-29 Cour Pharmaceuticals Development Company Inc. Covalent polymer-antigen conjugated particles
CA3009799A1 (en) * 2016-01-04 2017-07-13 Cour Pharmaceuticals Development Company Inc. Particles encapsulating fusion proteins containing linked epitopes
JP2019504895A (ja) * 2016-02-09 2019-02-21 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド スギ花粉エピトープを封入するtimp(組織性メタロプロテアーゼ阻害因子)
US11484506B2 (en) 2016-02-18 2022-11-01 Cour Pharmaceuticals Development Company, Inc. Process for the preparation of tolerizing immune-modulating particles
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
EP4215186A1 (en) 2018-02-08 2023-07-26 Cour Pharmaceuticals Development Company Inc. Treatment of celiac disease with tolerizing particles
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
EP3866835B1 (en) 2018-10-19 2024-01-03 The Regents Of The University Of Michigan Method for monitoring autoimmune disease
WO2020206439A1 (en) * 2019-04-05 2020-10-08 Nanocytomics, LLC Consumable components in fluidic sample dispensing systems and methods
CN110317255B (zh) * 2019-07-19 2020-07-31 北京工商大学 αs1-酪蛋白的抗原表位制备得到的单抗及牛乳过敏原检测方法
US20230086469A1 (en) * 2019-08-30 2023-03-23 Universidad De Chile Autoantigenic peptides (calvicifiv), presented by tolerogenic dentritic cells, useful for the personalized treatment of rheumatoid arthritis
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes
JP7471688B2 (ja) * 2019-12-03 2024-04-22 中國醫藥大學 オリゴペプチド、検出キット及び医薬組成物
WO2021155281A1 (en) * 2020-01-31 2021-08-05 Applied Molecular Transport Inc. Compositions and methods for treatment of celiac disease
MX2022011606A (es) * 2020-03-20 2022-12-08 Univ Monash Composiciones y metodos para tratar el lupus.
JP7349578B2 (ja) * 2020-10-27 2023-09-22 エルシダ オンコロジー, インコーポレイテッド 葉酸受容体に標的化されたナノ粒子薬物コンジュゲートおよびその使用
IL307688A (en) * 2021-04-16 2023-12-01 Cour Pharmaceuticals Dev Company Inc Treatment of peanut allergy with tolerogenic nanoparticles
JP2024518277A (ja) 2021-04-16 2024-05-01 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 免疫寛容の維持を追跡する方法
CA3235813A1 (en) 2021-10-21 2023-04-27 John J. Puisis Treatment of primary biliary cholangitis (pbc) with tolerizing nanoparticles
CN113908256B (zh) * 2021-11-26 2023-05-26 中国农业科学院兰州兽医研究所 Lancl1蛋白在制备抗病毒药物中的应用
CN114773434B (zh) * 2022-03-17 2024-04-05 南京市妇幼保健院 一种用于激活原始卵泡从而治疗或辅助治疗卵巢早衰的多肽pfap1及其应用
WO2023212341A1 (en) 2022-04-29 2023-11-02 Cour Pharmaceuticals Development Company Inc. Tolerizing immune modifying nanoparticles for overcoming the immunogenicity of therapeutic vectors and proteins
GB202211696D0 (en) * 2022-08-10 2022-09-21 Univ London Queen Mary Peptides and method
WO2024072751A1 (en) * 2022-09-26 2024-04-04 The Methodist Hospital Microparticle formulations for intravenous therapy and methods for their manufacture and use
WO2024086706A1 (en) 2022-10-19 2024-04-25 Cour Pharmaceuticals Development Company Inc. Treatment of peanut allergy with tolerizing nanoparticles
WO2024094562A1 (en) * 2022-11-01 2024-05-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3512940A (en) 1968-12-30 1970-05-19 Justin J Shapiro Test tube filter device
GB8311730D0 (en) 1983-04-29 1983-06-02 Bagshawe K D Handling of reaction mixtures
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4990253A (en) 1988-01-25 1991-02-05 Abbott Laboratories Fluid sample filtration device
US5358690A (en) 1989-01-10 1994-10-25 Lamina, Ltd. Environmental sample collection and membrane testing device
DE9013914U1 (sl) 1990-10-05 1991-02-14 Walter Sarstedt Geraete Und Verbrauchsmaterial Fuer Medizin Und Wissenschaft, 5223 Nuembrecht, De
CA2117492C (en) 1992-02-28 2009-04-07 Howard L. Weiner Bystander suppression of autoimmune diseases
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
JPH06157592A (ja) 1992-11-24 1994-06-03 Hitachi Chem Co Ltd ペプチドもしくはその誘導体、それらとタンパク質との結合体、及びこれらを免疫源とする抗エンドセリン−1抗体の製造方法
NZ266739A (en) 1993-06-02 1997-07-27 Tvw Telethon Inst Child Health Inducing immunologic tolerance by administering a cryptic peptide derived from the antigen der pi
US5833860A (en) 1995-08-28 1998-11-10 Millipore Investment Holdings Limited Centrifugal adsorptive sample preparation device and method
US5804201A (en) 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5
CA2285329A1 (en) 1997-03-31 1998-10-08 The Regents Of The University Of Michigan Open pore biodegradable matrices and process for making them
US7427602B1 (en) 1998-05-13 2008-09-23 The Regents Of The University Of Michigan Sustained DNA delivery from structural matrices
ATE378067T1 (de) 1999-08-18 2007-11-15 Industy Academic Cooperation F Agent zur induktion einer immunologischen toleranz
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7332168B2 (en) 2000-08-22 2008-02-19 Micromet Ag Composition for the elimination of autoreactive B-cells
US7029697B2 (en) 2001-02-14 2006-04-18 Northwestern University Controlled surface-associated delivery of genes and oligonucleotides
US6890556B1 (en) 2001-02-14 2005-05-10 Northwestern University Controlled surface-associated delivery of genes and oligonucleotides
US20020187147A1 (en) * 2001-02-15 2002-12-12 City Of Hope Antigen specific recombinant MHC class II molecules and methods of use
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
PT1487485E (pt) 2002-03-19 2011-03-11 Powderject Res Ltd Adjuvantes de imidazoquinolina para vacinas de adn
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS LIMITING THE EXTENSION OF PULMONARY INFECTIONS
CA2493081C (en) 2002-07-12 2013-04-23 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
US7465463B2 (en) 2002-09-04 2008-12-16 Polyheal, Ltd. Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues
US20060189554A1 (en) * 2002-09-24 2006-08-24 Russell Mumper Nanoparticle-Based vaccine delivery system containing adjuvant
WO2005000272A1 (en) * 2003-06-04 2005-01-06 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
US20060051407A1 (en) 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005015160A2 (en) 2003-08-07 2005-02-17 The Children's Hospital Of Philadelphia Functionalized polymeric colloids
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
WO2005020933A2 (en) 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
EP1687024B1 (en) 2003-11-05 2011-10-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
WO2007024323A2 (en) 2005-06-17 2007-03-01 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
DE602005015831D1 (de) 2004-04-02 2009-09-17 Research In Motion Ltd Einsatz und provisionierung drahtloser in der hand gehaltener einrichtungen
US7846466B2 (en) 2004-06-10 2010-12-07 Northwestern University Biodegradable scaffolds and uses thereof
JP2008512350A (ja) 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
ES2428510T3 (es) 2005-02-02 2013-11-08 Novo Nordisk A/S Derivados de insulina
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
ES2340197T3 (es) * 2005-07-01 2010-05-31 F. Hoffmann-La Roche Ag Particulas de latex carboxiladas.
US20070014752A1 (en) 2005-07-08 2007-01-18 Krishnendu Roy Surface functionalization of polymeric materials
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
US20070041934A1 (en) 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
JP2009519975A (ja) * 2005-12-16 2009-05-21 ユニバーシティ・オブ・カンザス 治療薬を送達するナノクラスター
US20100028450A1 (en) 2006-01-25 2010-02-04 The Board Of Trustees Of The University Of Illinoi S Tolerogenic biodegradable artificial antigen presenting system
US20090304726A1 (en) * 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007098557A1 (en) 2006-03-02 2007-09-07 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
JP2009533453A (ja) * 2006-04-11 2009-09-17 オードウェイ リサーチ インスティテュート 甲状腺ホルモン類似体、アンタゴニストおよびそれらの製剤のためのナノ粒子およびポリマー製剤
EP2061446A2 (en) * 2006-07-28 2009-05-27 University Court of the University of Edinburgh Use of cdk inhibitors for the treatment of granulocyte mediated disorders
EP3590503A1 (en) * 2006-10-12 2020-01-08 The University of Queensland Compositions and methods for modulating immune responses
US20090214474A1 (en) 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2672810C (en) 2006-12-18 2015-06-02 Colorobbia Italia S.P.A. Magnetic nanoparticles for the application in hyperthermia, preparation thereof and use in constructs having a pharmacological application
JP5650406B2 (ja) 2007-03-07 2015-01-07 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
US20080311140A1 (en) 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
EP2211841A4 (en) 2007-10-15 2013-03-13 Cooperative Res Ct For Asthma PROPHYLAXIS METHOD AND AGENTS FOR USE IN THIS METHOD
WO2009052561A1 (en) 2007-10-22 2009-04-30 The Walter And Eliza Hall Institute Of Medical Research Compositions and methods for manipulating an immune response
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
US20090123509A1 (en) * 2007-11-08 2009-05-14 Cory Berkland Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds
US20090238879A1 (en) 2008-01-24 2009-09-24 Northwestern University Delivery scaffolds and related methods of use
JP2009203174A (ja) 2008-02-26 2009-09-10 Hokkaido Univ タンパク質−リポソーム複合体を含有するイオントフォレーシス用組成物
EP2300022A2 (en) 2008-04-25 2011-03-30 Duke University Regulatory b cells and their uses
EP2123261A1 (en) 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
US20110206773A1 (en) 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
EP2349219A4 (en) * 2008-09-29 2013-05-01 Univ Mercer BIOLOGICALLY EFFECTIVE SUBSTANCES CAPSULATING NANO BEADS AND METHOD FOR FORMULATING NANO BEADS
AU2009298112B2 (en) 2008-10-02 2015-11-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Administration of an adsorbent polymer for treatment of systemic inflammation
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
BRPI0922122A2 (pt) * 2008-11-30 2017-08-01 Immusant Inc composições e métodos para tratamento de doença celíaca.
AU2009326818A1 (en) 2008-12-11 2011-07-07 The Govenors Of The University Of Alberta Methods and systems for inducing immunologic tolerance to non-self antigens
SG193843A1 (en) * 2009-01-20 2013-10-30 Univ Northwestern Compositions and methods for induction of antigen-specific tolerance
EP2255831A1 (en) * 2009-05-25 2010-12-01 Institut Pasteur Liposome based diepitope constructs
MX350667B (es) 2009-05-27 2017-09-12 Selecta Biosciences Inc Nanoportadores que poseen componentes con diferentes tasas de liberacion.
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
JP5486750B2 (ja) 2009-09-18 2014-05-07 国立大学法人九州大学 金微粒子被覆体とその製造方法、およびその用途
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
US20110135744A1 (en) 2009-12-03 2011-06-09 The Regents Of The University Of California Nanoparticle Based Therapy for Dispersing Mucin
EP2538969A4 (en) * 2010-02-22 2013-11-27 Liquidia Technologies Inc VACCINES FROM POLYSACCHARIDE PARTICLES
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
WO2011133617A1 (en) * 2010-04-23 2011-10-27 The Board Of Trustees Of The University Of Illinois Nano-hybrid delivery system for sequential utilization of passive and active targeting
WO2011150573A1 (en) 2010-06-04 2011-12-08 Tongji University Copolymer of pyrene and pyrrole and method of producing the copolymer
WO2011153532A1 (en) 2010-06-04 2011-12-08 Flow Pharma Inc. Peptide particle formulation
AU2011272941B2 (en) 2010-06-30 2014-05-29 Compugen Ltd. C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
JP5890407B2 (ja) * 2010-07-07 2016-03-22 アーティフィシャル セル テクノロジーズ インコーポレイテッド 呼吸器合胞体ウイルス抗原組成物および方法
CA2807141C (en) 2010-07-31 2019-02-26 The Scripps Research Institute Compositions and methods for inducing immune tolerance
WO2012019041A2 (en) 2010-08-04 2012-02-09 Duke University Regulatory b cells and their uses
CA2817755C (en) * 2010-11-12 2021-07-06 Rachael Terry Modified immune-modulating particles
SG10201509138XA (en) 2010-11-24 2015-12-30 Univ Nanyang Tech Method for coating particles with calcium phosphate and particles, microparticles and nanoparticles formed thereof
US10064406B2 (en) 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products
CN107028802A (zh) 2011-01-24 2017-08-11 耶路撒冷希伯来大学伊森姆研究发展有限公司 用于药物的经皮递送和全身性递送的纳米粒子
JP2014515007A (ja) * 2011-02-25 2014-06-26 サウス ダコタ ステート ユニバーシティー 局所送達のためのタンパク質ナノ担体
EP2704693A4 (en) 2011-04-29 2015-01-28 Selecta Biosciences Inc TAXED RELEASE OF IMMUNOSUPPRESSIVA FROM SYNTHETIC NANOTORIES
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
WO2013036303A2 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines
WO2013113326A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013115965A1 (en) * 2012-01-31 2013-08-08 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
EP3607973A1 (en) 2012-06-21 2020-02-12 Northwestern University Peptide conjugated particles
IL303425A (en) 2013-03-13 2023-08-01 Cour Pharmaceuticals Dev Company Secondary vaccine particles for the treatment of inflammation
EP3033102B2 (en) * 2013-08-13 2023-12-20 Northwestern University Peptide conjugated particles
US20160243221A1 (en) * 2013-10-18 2016-08-25 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems

Also Published As

Publication number Publication date
US10617747B2 (en) 2020-04-14
ES2762187T5 (es) 2024-06-17
IL243632B (en) 2020-04-30
RS59801B1 (sr) 2020-02-28
JP6553033B2 (ja) 2019-07-31
IL292567A (en) 2022-06-01
KR20240015725A (ko) 2024-02-05
DK3033102T4 (da) 2024-02-26
AU2023219813A1 (en) 2023-09-07
WO2015023796A3 (en) 2015-06-18
JP2021193086A (ja) 2021-12-23
FI3033102T4 (fi) 2024-03-01
HRP20192270T4 (hr) 2024-03-01
AU2014306603B2 (en) 2020-03-12
MX2020007079A (es) 2020-09-09
JP2016528254A (ja) 2016-09-15
US20150190485A1 (en) 2015-07-09
MX2016001931A (es) 2016-09-07
US20220008523A1 (en) 2022-01-13
IL273615A (en) 2020-05-31
EP3033102B2 (en) 2023-12-20
US20210000932A1 (en) 2021-01-07
AU2020203824A1 (en) 2020-07-02
CA2918823A1 (en) 2015-02-19
US20150283218A1 (en) 2015-10-08
DK3033102T3 (da) 2019-12-16
SI3033102T1 (sl) 2020-03-31
RS59801B2 (sr) 2024-03-29
RU2685186C2 (ru) 2019-04-16
ES2762187T3 (es) 2020-05-22
US20170258880A1 (en) 2017-09-14
US20200316181A1 (en) 2020-10-08
KR20210099186A (ko) 2021-08-11
KR20160042079A (ko) 2016-04-18
RU2016107998A (ru) 2017-09-18
PL3033102T3 (pl) 2020-09-07
PT3033102T (pt) 2019-12-19
US20180271962A1 (en) 2018-09-27
WO2015023796A2 (en) 2015-02-19
US11160851B2 (en) 2021-11-02
AU2020203824B2 (en) 2023-06-22
IL273615B (en) 2022-06-01
LT3033102T (lt) 2020-03-10
HUE047329T2 (hu) 2020-04-28
JP7408604B2 (ja) 2024-01-05
EP3033102B1 (en) 2019-10-23
EP3650047A1 (en) 2020-05-13
AU2014306603A1 (en) 2016-02-18
US10188711B2 (en) 2019-01-29
PL3033102T5 (pl) 2024-04-08
CN113332422A (zh) 2021-09-03
MX2023000194A (es) 2023-02-09
US11129881B2 (en) 2021-09-28
JP2024037982A (ja) 2024-03-19
MX2023000192A (es) 2023-02-09
EP3033102A4 (en) 2017-03-22
EP3033102A2 (en) 2016-06-22
CN105555301A (zh) 2016-05-04
JP7007335B2 (ja) 2022-02-10
RU2019110510A (ru) 2019-10-21
US11389517B2 (en) 2022-07-19
US9616113B2 (en) 2017-04-11
AU2020203822B2 (en) 2023-05-25
KR20220084202A (ko) 2022-06-21
MX2020004799A (es) 2020-10-19
US20170312349A1 (en) 2017-11-02
BR112016003084A2 (pt) 2017-09-12
US20220000994A1 (en) 2022-01-06
IL243632A0 (en) 2016-03-31
CY1122558T1 (el) 2021-01-27
KR102485789B1 (ko) 2023-01-05
CN105555301B (zh) 2021-04-16
US9522180B2 (en) 2016-12-20
ME03590B (me) 2020-07-20
AU2020203822A1 (en) 2020-07-02
JP2019196369A (ja) 2019-11-14
HRP20192270T1 (hr) 2020-06-12
KR20230008909A (ko) 2023-01-16

Similar Documents

Publication Publication Date Title
IL273615B (en) Peptide-conjugated particles
IL290884A (en) Particles are attached to the peptide
GB201303771D0 (en) Nanoparticles peptide compositions
HK1219058A1 (en) Peptides
GB201314411D0 (en) Peptide conjugates
HUE050164T2 (hu) Új négy-CTL epitóp-kapcsolt peptid
HK1211596A1 (en) Peptide
HK1211595A1 (en) Peptide
HK1198769A1 (en) Novel peptide
GB201315130D0 (en) Peptides
GB201303787D0 (en) Nanoparticle peptide compositions
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides